AI’s CRISPR-like breakthrough exposes unregulated gene-editing arms race and ethical blind spots in biotech governance
Original framing: “Anthropic’s discovery will, at best, be just another gene-editing tool” — New Scientist
Marginalized communities, including disabled rights advocates and global South populations, warn that gene-editing tools could exacerbate inequality by making 'enhancements' accessible only to the wealthy. For example, the *Convention on the Rights of Persons with Disabilities* (CRPD) explicitly opposes eugenics-adjacent technologies, yet such concerns are sidelined. Additionally, women’s health advocates highlight how gene-editing could be weaponized for reproductive control, echoing historical abuses like forced sterilization programs. These voices are systematically excluded from corporate and academic narratives.
The Anthropic-AI 'CRISPR-like' discovery is not an isolated scientific achievement but a symptom of a deeper crisis: the unchecked convergence of artificial intelligence, biotechnology, and corporate power, operating outside ethical and regulatory guardrails.
Historical patterns—from the recombinant DNA debates of the 1970s to the CRISPR patent wars—reveal how profit-driven innovation outpaces governance, while Indigenous and marginalized voices are systematically excluded from shaping these technologies. The absence of cross-cultural and trickster perspectives in mainstream narratives obscures the systemic risks, from ecological disruption to bio-surveillance, while reinforcing the myth of 'neutral' progress. To avert catastrophe, solutions must integrate Indigenous stewardship models, open-source governance, and global moratoria—treating gene-editing not as a tool to be wielded, but as a societal experiment requiring collective consent and oversight.